15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $1.1B | -$95M | 0.0% | -8.0% | $40M | — | $109M |
| 2024 | $1.3B | -$15M | 0.0% | -1.3% | $111M | — | $82M |
| 2023 | $2.0B | $73M | 0.0% | 5.6% | $235M | — | $17M |
| 2022 | $2.8B | $188M | 0.0% | 9.6% | $125M | $151M | $4M |
| 2021 | $1.7B | $132M | 0.0% | 8.3% | -$93M | $186M | $1M |
| 2020 | $836M | -$13M | 0.0% | -1.1% | $23M | $58M | $2M |
| 2019 | $822M | -$58M | 0.0% | -1.9% | $3M | $71M | $1M |
| 2018 | $816M | -$17M | 0.0% | -1.6% | $16M | $83M | $16M |
| 2017 | $865M | $38M | 0.0% | 1.4% | $40M | $93M | $26M |
| 2016 | — | $8M | — | — | $24M | $87M | $21M |
| 2015 | — | $4M | — | — | $16M | — | $2M |
| 2014 | — | -$32M | — | — | -$9M | — | $5M |
| 2013 | — | -$52M | — | — | $7M | — | $8M |
| 2012 | — | -$42M | — | — | $8M | — | $10M |
| 2011 | — | $4M | — | — | $14M | — | $11M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $241M | -$4M | 0.0% | -1.7% | $3M | — | $106M |
| Dec '25 | $237M | -$83M | 20.3% | -30.2% | $16M | — | $109M |
| Sep '25 | $250M | -$5M | 20.4% | -2.4% | $18M | — | $99M |
| Jun '25 | $274M | -$7M | 20.4% | -2.1% | $2M | — | $81M |
| Mar '25 | $293M | -$490000 | 20.0% | -0.3% | $4M | — | $81M |
| Dec '24 | $310M | -$4M | 20.0% | -1.1% | $22M | — | $82M |
| Sep '24 | $315M | $3M | 20.4% | 0.9% | $6M | — | $64M |
| Jun '24 | $340M | -$16M | 20.8% | -5.7% | $80M | — | $70M |
| Mar '24 | $379M | $3M | 20.4% | 0.8% | $4M | — | $5M |
| Dec '23 | $414M | $9M | 21.9% | 3.2% | $9M | — | $17M |
| Sep '23 | $442M | $13M | 22.0% | 4.6% | $67M | — | $14M |
| Jun '23 | $541M | $21M | 22.8% | 6.5% | $115M | — | $673000 |
| Mar '23 | $623M | $29M | 22.4% | 7.0% | $43M | — | $291000 |
| Dec '22 | $628M | $39M | 22.1% | 8.2% | $2M | $151M | $4M |
| Sep '22 | $636M | $35M | 22.6% | 8.2% | $138M | $133M | $30M |
| Jun '22 | $754M | $53M | 22.6% | 10.5% | $16M | $209M | $279000 |
| Mar '22 | $789M | $62M | 22.2% | 11.5% | -$31M | $225M | $1M |
| Dec '21 | $641M | $78M | 23.0% | 11.9% | -$76M | $186M | $1M |
| Sep '21 | $375M | $23M | 22.4% | 7.1% | -$5M | $106M | $842000 |
| Jun '21 | $332M | $12M | 21.9% | 4.8% | $14M | $118M | $18M |
How the market has priced CCRN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Cross Country Healthcare Inc's revenue has grown 4.7% per year. These are computed facts, not advice.
As of FY2025, Cross Country Healthcare Inc reported — of total debt against $109M of cash; operating income covered interest expense -38.1×.
In FY2025, gross margin was —, operating margin -8.0%, and net margin -9.0%.
As of Jun '26, Cross Country Healthcare Inc traded at a price-to-earnings ratio of about 4.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.